Ketorolac Trometamol Baxter Healthcare (Ketorolac Trometamol)

The drug works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for prostaglandin production. Lower prostaglandin levels reduce inflammation and interrupt pain signaling pathways, resulting in effective relief of acute pain.

The specific dose and duration of Ketorolac Trometamol are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and overall risk profile. Healthcare professionals follow local guidelines and product labeling to set an appropriate regimen.

Safety data for Ketorolac Trometamol during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under direct medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Ketorolac offers potent analgesia comparable to moderate‑dose opioids but without the risk of respiratory depression. Compared with other NSAIDs, it has a higher risk of renal and gastrointestinal adverse effects, so clinicians often reserve it for short‑term use when strong pain relief is needed quickly.

The injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discolored or contains particles.

Ketorolac Trometamol is given by intramuscular or intravenous injection. The route, injection site, and infusion rate are selected by the healthcare professional according to the clinical situation and patient tolerance.

The most critical risks include acute renal failure, severe bleeding or gastrointestinal ulceration, cardiovascular events such as myocardial infarction or stroke, and severe allergic reactions including anaphylaxis. Patients should be monitored closely for signs of these complications.

Ketorolac is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, those with active peptic ulcer disease, severe renal impairment, uncontrolled hypertension, and in the peri‑operative setting for coronary artery bypass graft surgery. Caution is also advised for patients on anticoagulants or with cardiovascular disease.